All In Biotech

Drug Trial Radar · NCT01212471

A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease

Last checked: Nov 20, 2026Latest source record: Sep 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 840 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

840

Actual

Start

Sep 2010

Primary completion

Aug 2011

Study completion Dec 2011

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Sep 30, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.

Conditions

  • Dry Eye Syndrome

Interventions

  • Bromfenac Ophthalmic Solution ADrug

    sterile ophthalmic solution

  • Bromfenac Ophthalmic Solution BDrug

    sterile ophthalmic solution

  • Placebo ComparatorDrug

    sterile ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Ocular Surface Disease Index (OSDI) Total ScoreTime frame: 42 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ISTA Pharmaceuticals, Inc.

    Irvine, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.